Latest Allarity Therapeutics News & Updates

See the latest news and media coverage for Allarity Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Allarity Therapeutics

Clinical-stage precision medicine company for oncology

allarity.com
Headquarters
Tarpon Springs, United States
Founded year
2012
Company type
Public company
Number of employees
10–50

Latest news about Allarity Therapeutics

Company announcements

  • Allarity Therapeutics

    Allarity Therapeutics secures US notice of patent allowance

    The USPTO issued a Notice of Allowance for the stenoparib DRP® test; patent is expected to grant within three months, potentially providing exclusivity into at least 2039.

  • Allarity Therapeutics

    Allarity Therapeutics presents two AACR 2026 posters on stenoparib

    Posters highlight stenoparib's potential in colorectal cancer via WNT modulation and DRP® linking to improved ovarian cancer survival. Posters available on website.

  • Allarity Therapeutics

    Allarity Therapeutics reports 2025 financial results

    Cash position stands at $14.7M with runway to mid-2028. Stenoparib gains FDA Fast Track for ovarian cancer and launches VA-funded lung cancer study. Net loss improves to $11.2M.

  • Allarity Therapeutics

    Allarity Therapeutics closes $20 million financing

    The non-convertible debt from Streeterville Capital extends cash runway to mid-2028 and funds Phase 2 ovarian cancer trial completion, FDA preparations, and stenoparib commercialization.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Allarity Therapeutics

Track Allarity Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Allarity Therapeutics competitors & trending companies

Browse news for competitors to Allarity Therapeutics and other trending companies.